Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Takeda Logs 3.6% Sales Rise, Double-Digit Profit Jump on Entyvio, Takecab
November 2, 2017
- Astellas Delivers Positive Data in 1st HIF-PH Inhibitor Study in Japan
November 1, 2017
- Aspen Takes Over Arixtra from GSK, Transfer Pact Completed in Japan
November 1, 2017
- Bristol-Myers France’s Barland to Become Japan President
November 1, 2017
- Kyowa Kirin Kicks Off Japan PIII for Regpara Follow-Up Evocalcet
November 1, 2017
- Daiichi Sankyo Shooting for Top Share for Lixiana by Tokyo Olympics: President
November 1, 2017
- Daiichi Sankyo Ekes Out 2.5% Sales Rise despite Olmetec LOE, Operating Profit Sags 33.5%
November 1, 2017
- Micardis Generic Penetration “Faster than Expected”: Astellas President
November 1, 2017
- Towa to Discontinue Sales of 34 Products due to Bulk Drug Supply Problems, Weak Demand
November 1, 2017
- Sumitomo Dainippon In-Licenses Diabetes Med from France’s Poxel
November 1, 2017
- Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
November 1, 2017
- Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
November 1, 2017
- Parkinson’s Disease Therapy Rasagiline Improves Average Daily Off-Time in Japan PII/PIII Study: Takeda
November 1, 2017
- Daiichi Sankyo Pairs Up with German Startup to Develop ADC for Solid Cancer
November 1, 2017
- Boehringer, Astellas to Extend Sales Pact for Micardis Family of Products to March 2020
November 1, 2017
- Sumitomo Dainippon Beats 1st Half Guidance, Ups Full-Year Outlook
October 31, 2017
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
- JT, Torii to Jointly Develop HIF-PH inhibitor in Japan
October 30, 2017
- JCR Starts Development of Another BBB-Penetrating Drug for Hurler Syndrome
October 30, 2017
- Mogamulizumab Accepted for Review in Europe: Kyowa Kirin
October 30, 2017
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…